Management of Inflammatory breast cancer: current concepts

Awad Ali M. Alawad

ABSTRACT

Abstract is not required for Editorial
Management of Inflammatory breast cancer: current concepts

Awad Ali M. Alawad

Inflammatory breast cancer (IBC) is considered as the most aggressive type of locally advanced breast cancer that carries an appreciably poor prognosis. Sir Charles Bell described the first case of IBC in literature. It was reported and published in 1814 by Sir Charles Bell [1]. Clinically, IBC is defined by characteristics features, including rapid onset within short time, erythema, edema of the breast, and a “peau d’orange” appearance to most areas of breast skin. Moreover, patients presented with positive metastatic lymph node involvement and up to one fourth of patients have distant metastases at time of diagnosis [2]. Pathologically, the presence of dermal lymphatic tumor emboli is considered as the hallmark of IBC. Previously, single modality treatment to manage IBC had failed. The majority of patients developed recurrence and/or metastases within short time, and 5-year survival rate was less than 5%.

Today, the general consensus is that patients with IBC without proof of metastases at the time of diagnosis should receive neoadjuvant chemotherapy followed by surgery followed by radiotherapy. For patients with human epidermal growth factor receptor (HER2) disease, trastuzumab (an antibody targeting HER2) is recommended. For patients with hormone receptor–positive disease, hormonal therapy is indicated. Regarding chemotherapy, the sequence of taxane-based chemotherapy followed by anthracycline-based chemotherapy is the cornerstone of primary chemotherapy for IBC [3]. Among patients with IBC, response to neoadjuvant chemotherapy plays a comparable prognostic role to that observed among patients with non-IBC.

Mastectomy is generally considered an important part of the multimodality treatment of IBC. The only method of definitive surgery offered to patients with IBC following neoadjuvant chemotherapy is modified radical mastectomy. Skin-sparing mastectomy and breast conserving surgery are contraindicated for patients with IBC [4]. Postmastectomy chest wall radiotherapy (RT) is generally indicated for patients with inflammatory breast cancer who are treated with neoadjuvant chemotherapy.

Understanding the biological characteristics of the disease has allowed for the development of targeted therapies (e.g., trastuzumab and lapatinib) that are improving the outcome of this aggressive disease. Human epidermal growth factor receptor 2 (HER2) positive patients should receive HER2 targeted therapy with neoadjuvant chemotherapy. Trastuzumab should be continued after surgery to complete one year of treatment [5]. Lapatinib is an orally active small molecule that reversibly inhibits the tyrosine kinase component of both HER2 and epidermal growth factor receptor-1 (ErbB-1). A recent research showed that lapatinib in conjunction with chemotherapy reduces the risk of disease progression by 50% in women with inflammatory breast cancer whose disease had progressed on trastuzumab-containing chemotherapy regimens [5]. Other agents that are presently being evaluated for the treatment of IBC include antiangiogenic agents and Ras pathway inhibitors. IBC is known to be highly vascular that express a number of angiogenic factors such as vascular endothelial growth factor (VEGF). This encouraged a number of studies looking at the role of anti-VEGF agents (e.g., bevacizumab) combined with chemotherapy in the treatment of IBC, with hopeful results [5, 6].

Combinations of neoadjuvant chemotherapy, mastectomy, and radiotherapy have led to an improved prognosis. However, the overall five-year survival rate for patients with IBC is still very low, at ∼20% [7]. Proper management of IBC requires close coordination.
among surgical, radiation oncologists, radiologists, and pathologists. It is important for health institutions to pool resources by establishing a tumor registry for collecting data from patients with IBC worldwide to deal with this fatal disease because of the infrequency of IBC.

How to cite this article
doi:10.5348/ijcri-201502-ED-10002

Author Contributions
Awad Ali M. Alawad – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Guarantor
The corresponding author is the guarantor of submission.

Conflict of Interest
Authors declare no conflict of interest.

Copyright
© 2015 Awad Ali M. Alawad. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

REFERENCES
Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.

Most Favored Author program
Join this program and publish any number of articles free of charge for one to five years.

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

We welcome you to interact with us, share with us, join us and of course publish with us.

CONNECT WITH US